Top ▲
target has curated data in GtoImmuPdb
Target id: 2887
Nomenclature: tryptophan 2,3-dioxygenase
Abbreviated Name: TDO2
Family: 1.13.11.- Dioxygenases
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 406 | 4q32.1 | TDO2 | tryptophan 2,3-dioxygenase | |
Mouse | - | 406 | 3 E3 | Tdo2 | tryptophan 2,3-dioxygenase | |
Rat | - | 406 | 2q34 | Tdo2 | tryptophan 2,3-dioxygenase |
Previous and Unofficial Names |
tryptophan peroxidase | tryptophan pyrrolase | tryptophanase | indolamine 2,3-dioxygenase | tryptamine 2,3-dioxygenase | TDO | TPH2 | tryptophan 2 |
Database Links | |
Alphafold | P48775 (Hs), P48776 (Mm), P21643 (Rn) |
BRENDA | 1.13.11.11 |
ChEMBL Target | CHEMBL2140 (Hs), CHEMBL1075307 (Mm), CHEMBL2686 (Rn) |
Ensembl Gene | ENSG00000151790 (Hs), ENSMUSG00000028011 (Mm), ENSRNOG00000011612 (Rn) |
Entrez Gene | 6999 (Hs), 56720 (Mm), 64206 (Rn) |
Human Protein Atlas | ENSG00000151790 (Hs) |
KEGG Enzyme | 1.13.11.11 |
KEGG Gene | hsa:6999 (Hs), mmu:56720 (Mm), rno:64206 (Rn) |
OMIM | 191070 (Hs) |
Pharos | P48775 (Hs) |
RefSeq Nucleotide | NM_005651 (Hs), NM_019911 (Hs), NM_022403 (Rn) |
RefSeq Protein | NP_005642 (Hs), NP_064295 (Mm), NP_071798 (Rn) |
UniProtKB | P48775 (Hs), P48776 (Mm), P21643 (Rn) |
Wikipedia | TDO2 (Hs) |
Enzyme Reaction | ||||||||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific inhibitor tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibitor Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LM10 is >640-fold selective for TDO2 over IDO1 [3]. |
Immunopharmacology Comments |
Depletion of tryptophan and metabolites promote Treg cell differentiation, suppression of immune response and decreased DC function. TDO2 inhibition reverses this [3]. |
1. Dolusić E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B, Masereel B, Wouters J et al.. (2011) Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem, 54 (15): 5320-34. [PMID:21726069]
2. Dounay AB, Tuttle JB, Verhoest PR. (2015) Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. J Med Chem, 58 (22): 8762-82. [PMID:26207924]
3. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B et al.. (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA, 109 (7): 2497-502. [PMID:22308364]
1.13.11.- Dioxygenases: tryptophan 2,3-dioxygenase. Last modified on 03/07/2019. Accessed on 08/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2887.